Research programme: anti-Ebola monoclonal antibodies - Medicago/Public Health Agency of Canada
Latest Information Update: 28 Mar 2019
At a glance
- Originator Medicago; Public Health Agency of Canada
- Class Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ebola virus infections
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for research development in Ebola-virus-infections in Canada
- 24 Feb 2015 Early research in Ebola virus infections in Canada (unspecified route)